Publication: 2809

Publication: 2809

Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Clin Cancer Res vol 24 (21) 5292-304

Year:: 2018
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 8

Parents:: 2540 2925
Children:: None

Program:: TRP
Primary Committee:: Sequencing
Sec. Committees:: Breast

Pharmas:
Grants:: U10CA180821, U10CA180882, U10CA180791, U10CA180833, U10CA180838, U10CA180858, U10CA180867, P50-CA58223-09A1, U10CA180888, U10CA180801, U24CA196171

Corr. Author:
Authors:: Maki Tanioka Cheng Fan Joel S Parker Katherine A Hoadley Zhiyuan Hu Yan Li Terry M Hyslop Brandelyn N Pitcher Matthew G Soloway Patricia A Spears Lynn N Henry Sara Tolaney Chau T Dang Ian E Krop Lyndsay N Harris Donald A Berry Elaine R Mardis Eric P Winer Clifford A Hudis Lisa A Carey Charles M Perou

Networks:: KAISER, LAPS-CT018, LAPS-MA036, LAPS-NC007, LAPS-NY016

Study: CALGB-40601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: